Skip to main content
Home / Resources / Conferences / BIO Europe

BIO Europe

BIO Europe

Flexible solutions for biotech companies at every value inflection point

Expertise for Every Modality in Early Development

Certara offers new, emerging and VC-backed biotech companies a modern and data driven approach to drug development. Starting with the end in mind, Certara’s cross functional experts will support your team to further your scientific insights, optimize resources, and de-risk your therapy development journey.

Expertise for every modality:

  • Small molecules, Biologics (monoclonal antibodies, ADCs)
  • Complex biologics (Bispecific Abs, siRNA, oligonucleotides)
  • Cell and Gene Therapies, Vaccines, Drug-device combos and Devices

Certara Strategy Early Development Solutions
Expert support at every stage from Candidate Selection Through Phase 1

Successfully navigating the challenges of moving from candidate selection to successful Phase 1 program requires significant experience and expertise in drug development. Pharmaceutical development poses unique challenges due to its high cost, long duration and high attrition. Ensuring your candidate takes the optimal approach throughout early development is critical. Achieving success in the early stages paves the way for securing funding and partnership opportunities, positioning you for continued success in subsequent phases.

Strategic Partnerships for Early Development Success

Are you spending too much time managing multiple consultants/vendors, telling them what to do, and hoping your timelines don’t slip? Certara offers a strategic partnership that streamlines your early development work, allowing you to focus on what matters most.

Certara’s solutions:

  • A full team of cross-functional virtual drug developers 
  • Relationships with individual experts who become an integrated part of your team 
  • Strategic recommendations from a collaborative partner invested in your success 

Certara played a key role in Biohaven’s approval of Nurtec, contributing to the company’s acquisition by Pfizer for almost $12B. Check out a video testimonial here.

Our comprehensive services have recently helped clients:

  • Achieve an accelerate approval in pediatric oncology  
  • Avoid the costly expense of entering Phase 1 with a starting dose that was too low 
  • Reach significant milestones in development and regulatory approval

Additional Resources